This study evaluated the impact of prior lines of therapy on the efficacy of CAR-T and ASCT and found that OS was significantly longer, with a trend toward longer PFS, for patients who received CAR-T after two lines of chemotherapy compared to those who received three or more lines of prior chemotherapy.
Log In with AHPRA